more

Masimo (MASI)

(Real Time Quote from BATS)

$142.07 USD

+2.13 (1.52%)

Updated Oct 9, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

Top 37% (94 out of 252)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Gets FDA Nod for RRp Monitoring Technology

by Zacks Equity Research Published on March 03,2020

The FDA clearance of this monitoring system is expected to strengthen Masimo's (MASI) portfolio of pulse oximetry technologies.

medical

Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

by Zacks Equity Research Published on February 21,2020

Masimo (MASI) sees expansion in gross and operating margin in Q4.

COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus

by Sriparna Ghosal Published on January 24,2020

Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.

medical

Masimo Posts Solid Preliminary 2019 Results, Issues Guidance

by Zacks Equity Research Published on January 15,2020

Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.

medical

Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod

by Zacks Equity Research Published on January 02,2020

Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.

medical

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research Published on December 26,2019

Masimo (MASI) raises revenue and earnings guidance for 2019.

medical

Masimo (MASI) Expands Partnership with Texas-Based Drager

by Zacks Equity Research Published on December 20,2019

Masimo (MASI) sees a slew of developments in recent times.

medical

Digital Health Gaining Momentum: 3 MedTech Stocks in Focus

by Trina Mukherjee Published on November 21,2019

Digital health is committed to changing the face of healthcare as evident from its innovative solutions for the betterment of patients' lives.

medical

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research Published on November 21,2019

Masimo (MASI) raises 2019 revenue and EPS guidance.

medical

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

by Zacks Equity Research Published on October 31,2019

Masimo (MASI) raises its 2019 product revenue guidance.

Masimo (MASI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research Published on October 30,2019

Masimo (MASI) delivered earnings and revenue surprises of 7.04% and 3.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MASIPositive Net Change

Medical Products' Oct 30 Earnings Roster: MCK, MASI & More

by Zacks Equity Research Published on October 29,2019

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.

Masimo (MASI) Reports Next Week: What You Should Expect

by Zacks Equity Research Published on October 23,2019

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MASIPositive Net Change

Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now

by Zacks Equity Research Published on September 30,2019

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.

medical

Cerner (CERN) Set to Improve Patient Experience With New Deal

by Zacks Equity Research Published on September 25,2019

The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.